







an Open Access Journal by MDPI

Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Scrutinizing the Soldiers and the Weapons in the Tumor Milieu

Guest Editors:

Dr. Antonella Argentiero

Medical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, 70124 Bari, Italy

Dr. Antonio G. Solimando

Unit of Internal Medicine "Guido Baccelli", Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, 70124 Bari, Italy

Deadline for manuscript submissions:

closed (31 October 2023)

Message from the Guest Editors

Dear Colleagues,

It is our pleasure to invite you to contribute to the upcoming Special Issue of the journal *Cancers* entitled "Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Scrutinizing the Soldiers and the Weapons in the Tumor Milieu". The aim of this Special Issue is to provide an overview of current knowledge on the crucial mechanisms that promote tumor niche interactions and mediate immunosuppression during pancreatic cancer development and progression.

A major challenge in the treatment of patients with PDAC is the timely identification of treatment options in a personalized manner. Current approaches in precision oncology aim to match specific DNA mutations to drugs, but the incorporation of genome-wide RNA, DNA, epigenetics and proteomics profiles has not yet been clinically assessed.

All manuscripts will be peer-reviewed according to standard journal procedures and policies.

We hope that you will be able to accept this invitation and contribute to the success of this Special Issue. I look forward to collaborating with you.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us